News and Analysis

Filter By:

Article Type
  • A historic amount of capital flowed to newly public biotech companies in 2018.

    • Chris Morrison
    News and Analysis
  • With clinical failures mounting and companies disinvesting, researchers are revising the cancer stem cell model.

    • Ken Garber
    News and Analysis
  • With the FDA's approval of GlaxoSmithKline's tafenoquine, global health experts will at last have access to a long-awaited new treatment forPlasmodium vivax recurrence. Much-needed novel treatments for the more common Plasmodium falciparumare in phase II trials.

    • Asher Mullard
    News and Analysis
  • Ongoing and upcoming clinical trials of metformin, mTOR inhibitors and senescent cell-killing drugs could prove that ageing and ageing-related diseases are viable drug discovery indications.

    • Asher Mullard
    News and Analysis
  • Constrained peptides have long tantalized drug developers with their potential ability to combine the best attributes of antibodies and small molecules. Finally, a handful of constrained peptides are in late-stage clinical trials.

    • Chris Morrison
    News and Analysis
  • Amgen's erenumab recently secured FDA approval as the first G protein-coupled receptor-targeted antibody. More of these biologics are on the way, despite remaining challenges.

    • Elie Dolgin
    News and Analysis
  • Two immune-boosting strategies have independently indicated promise in sepsis clinical trials, after years of failures with anti-inflammatories in this same space. Will it be enough to take sepsis drug development out of 'critical condition'?

    • Asher Mullard
    News and Analysis
  • Many drugs unexpectedly influence the human gut microbiome, showed a recent study, prompting questions about toxicity assays, clinical implications and repurposing opportunities.

    • Cassandra Willyard
    News and Analysis
  • With Alnylam's rare disease drug candidate patisiran nearing the regulatory finish line, the RNA interference community is now turning its attention to next-generation delivery technology to solidify the future of the emerging modality.

    • Chris Morrison
    News and Analysis
  • The FDA approved 46 new drugs last year, the highest total in more than two decades.

    • Asher Mullard
    News and Analysis